Flovent HFA Administration and Dosing
Flovent HFA (fluticasone propionate) is administered as an oral inhalation twice daily, with dosing based on age and asthma severity, starting at 88 mcg twice daily for most patients and titrating to the lowest effective dose that maintains control. 1
Dosing by Age Group
Adults and Adolescents (≥12 years)
- Starting dose: 88 mcg twice daily
- Maximum dose: 880 mcg twice daily
- Low dose: 88-264 mcg/day
- Medium dose: >264 to 440 mcg/day
- High dose: >440 mcg/day 2, 1
Children (4-11 years)
- Standard dose: 88 mcg twice daily
- Low dose: 88-176 mcg/day
- Medium dose: >176-352 mcg/day
- High dose: >352 mcg/day 2, 1
Young Children (<4 years)
- Low dose: 176 mcg/day (divided twice daily)
- Requires face mask delivery for optimal dosing
- Higher dose needed than older children due to lower delivery efficiency with face mask 2
Proper Administration Technique
Prime the inhaler before first use or if not used for >7 days. Shake well before each use. The patient should:
- Exhale fully away from the inhaler
- Place the mouthpiece in mouth with lips sealed around it
- Inhale slowly and deeply while pressing down on the canister
- Hold breath for 10 seconds
- Rinse mouth with water and spit out after each use to reduce risk of oral candidiasis 1
A spacer or valved holding chamber is recommended to improve delivery and reduce local side effects 2.
Stepwise Treatment Approach
The NAEPP guidelines position Flovent HFA within a stepwise approach 3, 2:
- Step 2 (Mild Persistent): Low-dose ICS as preferred therapy
- Step 3 (Moderate Persistent): Low-dose ICS + LABA OR medium-dose ICS
- Step 4 (Moderate-Severe): Medium-dose ICS + LABA
- Step 5-6 (Severe): High-dose ICS + LABA ± additional controllers
Important caveat: Long-acting beta-agonists should never be used as monotherapy and must always be combined with an inhaled corticosteroid due to increased risk of severe exacerbations and death when used alone 3.
Dose Titration Principles
The most critical principle is titrating to the lowest effective dose that maintains control. 2, 1 Once asthma control is achieved for at least 3 months, attempt to step down therapy. The dose-response curve for fluticasone is relatively flat, with 80-90% of maximum benefit achieved at 200-250 mcg/day in adults 4, 5. Higher doses provide marginal additional benefit but substantially increase systemic side effect risk.
Key Safety Considerations
Monitor for Systemic Effects
- Growth suppression in children (measure height regularly) 1
- Adrenal suppression with high doses or prolonged use 1
- Bone mineral density reduction with long-term use 1
- Glaucoma and cataracts with chronic use 1
Local Side Effects
- Oral candidiasis (5-10% incidence)
- Dysphonia (hoarseness)
- Cough
- Prevention: Mouth rinsing after each use significantly reduces these risks 1
Drug Interactions
Avoid concurrent use with strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin) as these can dramatically increase systemic fluticasone exposure and cause Cushing syndrome or adrenal suppression 1.
Special Populations
Oral corticosteroid-dependent asthma: Fluticasone 2000 mcg/day is more effective than 1000-1500 mcg/day for reducing oral prednisolone requirements 5. However, this high dose carries significant systemic risk and requires close monitoring.
Hepatic impairment: Monitor closely for increased drug exposure and systemic effects 1.
Common Pitfalls to Avoid
- Not rinsing mouth after use - leads to preventable oral candidiasis
- Using as rescue medication - Flovent HFA is maintenance therapy only, not for acute bronchospasm 1
- Prescribing unnecessarily high doses - doses above 200-250 mcg/day provide minimal additional benefit in most patients 4, 5
- Failing to step down therapy - once control is achieved, attempt dose reduction to minimize systemic effects 2
- Abrupt discontinuation - taper slowly to avoid adrenal crisis, especially in patients on high doses 1